SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses.

Details

Serval ID
serval:BIB_548438B21610
Type
Article: article from journal or magazin.
Collection
Publications
Title
SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses.
Journal
Cell reports
Author(s)
Chatterjee D., Tauzin A., Marchitto L., Gong S.Y., Boutin M., Bourassa C., Beaudoin-Bussières G., Bo Y., Ding S., Laumaea A., Vézina D., Perreault J., Gokool L., Morrisseau C., Arlotto P., Fournier É., Guilbault A., Delisle B., Levade I., Goyette G., Gendron-Lepage G., Medjahed H., De Serres G., Tremblay C., Martel-Laferrière V., Kaufmann D.E., Bazin R., Prévost J., Moreira S., Richard J., Côté M., Finzi A.
ISSN
2211-1247 (Electronic)
Publication state
Published
Issued date
01/03/2022
Peer-reviewed
Oui
Volume
38
Number
9
Pages
110429
Language
english
Notes
Publication types: Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
Continuous emergence of SARS-CoV-2 variants of concern (VOCs) is fueling the COVID-19 pandemic. Omicron (B.1.1.529) rapidly spread worldwide. The large number of mutations in its Spike raise concerns about a major antigenic drift that could significantly decrease vaccine efficacy and infection-induced immunity. A long interval between BNT162b2 mRNA doses elicits antibodies that efficiently recognize Spikes from different VOCs. Here, we evaluate the recognition of Omicron Spike by plasma from a cohort of SARS-CoV-2 naive and previously infected individuals who received their BNT162b2 mRNA vaccine 16 weeks apart. Omicron Spike is recognized less efficiently than D614G, Alpha, Beta, Gamma, and Delta Spikes. We compare with plasma activity from participants receiving a short (4 weeks) interval regimen. Plasma from individuals of the long-interval cohort recognize and neutralize better the Omicron Spike compared with those who received a short interval. Whether this difference confers any clinical benefit against Omicron remains unknown.
Keywords
Adult, Aged, Antibodies, Neutralizing/analysis, Antibodies, Neutralizing/blood, Antibodies, Neutralizing/immunology, Antibodies, Viral/analysis, Antibodies, Viral/blood, Antibodies, Viral/immunology, BNT162 Vaccine/administration & dosage, BNT162 Vaccine/immunology, Cohort Studies, Female, HEK293 Cells, Humans, Immunization Schedule, Immunization, Secondary/methods, Male, Middle Aged, Quebec, SARS-CoV-2/immunology, SARS-CoV-2/pathogenicity, Spike Glycoprotein, Coronavirus/immunology, Time Factors, Vaccination/methods, Vaccine Potency, Vaccines, Synthetic/administration & dosage, Vaccines, Synthetic/immunology, Young Adult, mRNA Vaccines/administration & dosage, mRNA Vaccines/immunology, COVID-19, Coronavirus, Omicron, SARS-CoV-2, delayed mRNA vaccine regimen, humoral responses, neutralization, spike glycoproteins, variants of concern
Pubmed
Web of science
Open Access
Yes
Create date
09/05/2023 12:59
Last modification date
29/11/2024 13:40
Usage data